Bill Anderson/LinkedIn
Nov 26, 2025, 11:37
Bill Anderson on Secondary Stroke Prevention: This Week, We’ve Reached a Significant Milestone
Bill Anderson, CEO at Bayer, shared on LinkedIn:
”Those numbers tell the story: stroke is devastating.
For patients. For families.
And after surviving, the risk of another stroke is even higher.
This week, we’ve reached a significant milestone with positive topline results from our international Phase III study in secondary stroke prevention.
Our teams worked hard to get here.
Thank you, Team Bayer, for pushing to help people who’ve already been through so much.
We’re making progress—and there’s more to do.”
Stay updated with Hemostasis Today.
-
Jan 13, 2026, 13:03Claudio Laudani on Dual Versus Single Antiplatelet Therapy
-
Jan 13, 2026, 12:46Stephanie Carlin and Colleagues on Clinical Outcomes of DOAC-Anticonvulsant Coprescription
-
Jan 13, 2026, 10:53Lena Volland on Ming Y Lim’s Example of Designing Care Models for WGBD Community With Intention
-
Jan 13, 2026, 05:05Pablo Corral Shares Key Takeaways on Reducing LDL-Cholesterol to Very Low Levels
-
Jan 13, 2026, 04:49Martin Haluzík Shares A Study on GLP1-1RAs Use in Peripheral Artery Disease and DM
-
Jan 13, 2026, 04:37Shreya Agarwal and Bryce A Kerlin on The Impact of Advanced Hemostasis and Thrombosis Fellowship Trainings
-
Jan 13, 2026, 03:53Christian Schulze Shares New Data from DANGERSHOCK
-
Jan 13, 2026, 03:39Samwel Mikaye Breaks Down Peripheral Blood Smear
-
Jan 12, 2026, 20:15Mazou Ngou Temgoua on SCAF: Subclinical Atrial Fibrillation on Treatment with Apixaban or Aspirin